OPK vs LH vs DGX vs EXAS vs BIO

For growth investors, Exact Sciences Corporation (EXAS) is the stronger pick with 17.

7% revenue growth year-over-year, versus -14. 9% for OPKO Health, Inc. (OPK). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 2x trailing P/E (25. 0x forward), making it the more compelling value choice. Analysts rate OPKO Health, Inc. (OPK) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bio-Rad Laboratories, Inc.

(BIO) is the cheapest at 9. 2x versus Labcorp Holdings Inc. at 24. 7x. On forward P/E, Labcorp Holdings Inc. is actually cheaper at 14. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Quest Diagnostics Incorporated (DGX) delivered a total return of +47.

7%, compared to -70. 5% for OPKO Health, Inc. (OPK). Over 10 years, the gap is even starker: EXAS returned +1669% versus OPK's -89. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Quest Diagnostics Incorporated (DGX) is the lower-risk stock at 0.

07β versus OPKO Health, Inc. 's 1. 25β — meaning OPK is approximately 1606% more volatile than DGX relative to the S&P 500. On balance sheet safety, Bio-Rad Laboratories, Inc. (BIO) carries a lower debt/equity ratio of 21% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Exact Sciences Corporation (EXAS) is pulling ahead at 17.

7% versus -14. 9% for OPKO Health, Inc. (OPK). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to -291. 1% for OPKO Health, Inc.. Over a 3-year CAGR, EXAS leads at 15. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus -37. 2% for OPKO Health, Inc. — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DGX leads at 14. 5% versus -36. 1% for OPK. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Labcorp Holdings Inc.

(LH) trades at 14. 5x forward P/E versus 582. 8x for Exact Sciences Corporation — 568. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPK: 156. 2% to $2. 87.

In this comparison, DGX (1.

6% yield), LH (1. 1% yield) pay a dividend. OPK, EXAS, BIO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, OPK: -89. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OPK is a small-cap quality compounder stock; LH is a mid-cap quality compounder stock; DGX is a mid-cap quality compounder stock; EXAS is a mid-cap high-growth stock; BIO is a small-cap deep-value stock. LH, DGX pay a dividend while OPK, EXAS, BIO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.